ArticleCell2017
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 233 papers.
0numbers the graph read from it
0cells of the map it votes in
233citing papers in PubMed
46.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
233 citing papers in PubMed, 348 citations in OpenAlex.
- Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.Frontiers in immunology · 2024Trial
- Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes.The Journal of experimental medicine · 2019Trial
- Signatures of the neutralizing dengue virus-reactive memory B cell repertoire identified by multiplexed envelope dimer probes.medRxiv : the preprint server for health sciences · 2026Article
- Structural basis of diverse antibody recognition of conserved coronavirus spike S2 epitopes that contribute to protective immunity.bioRxiv : the preprint server for biology · 2026Article
- Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies.bioRxiv : the preprint server for biology · 2026Article
- Review
- A Zika virus vaccine with E protein fusion loop mutations protects via CD8Nature microbiology · 2026Article
- Potent Cross-Serotype Dengue Neutralization with Low ADE by AG-Strand-Targeting Anti-EDIII Antibodies.ACS omega · 2026Article
- Article
- Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Protective human antibodies against Powassan virus.Journal of virology · 2026Article
- Targeting the Zika virus envelope domains I and III as a recombinant vaccine protects mice from lethal challenge.NPJ vaccines · 2026Article
- Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026Article
- Ten years of Zika in Brazil: achievements, challenges and perspectives.Virology journal · 2026Review
- Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations.International journal of molecular sciences · 2026Review
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk.Nature communications · 2025Article
- Generation of a Human-Mouse Chimeric Anti-Japanese Encephalitis Virus and Zika Virus Monoclonal Antibody Using CDR Grafting.Microorganisms · 2025Article
- Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial.Nature medicine · 2025Article
- Bioprofiling and vaccine development for Zika virus.Science China. Life sciences · 2025Review
173 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 6 institutions in 2 countries.
Davide F RobbianiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA. Electronic address: drobbiani@rockefeller.edu.
Leonia BozzaccoLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Ricardo KhouriInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil.
Priscilla C OlsenLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Anna GazumyanLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Dennis Schaefer-BabajewLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Santiago Avila-RiosNational Institute of Respiratory Diseases, Mexico City CP 14080, Mexico.
Lilian NogueiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Roshni PatelLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Stephanie A AzzopardiLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Lion F K UhlLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Mohsan SaeedLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Edgar E Sevilla-ReyesNational Institute of Respiratory Diseases, Mexico City CP 14080, Mexico.
Marianna AgudeloLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Kai-Hui YaoLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Jovana GolijaninLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Harry B GristickDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Yu E LeeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Arlene HurleyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Joy PaiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Thiago OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Elsio A WunderInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA.
Gielson SacramentoInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil.
Nivison NeryInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil.
Cibele OrgeInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil.
Federico CostaInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA; Faculdade de Medicina da Bahia and Instituto da Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia CEP 40296-710, Brazil.
Mitermayer G ReisInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA; Faculdade de Medicina da Bahia and Instituto da Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia CEP 40296-710, Brazil.
Neena M ThomasLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Thomas EisenreichLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Daniel M WeinbergerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA.
Antonio R P de AlmeidaFaculdade de Medicina da Bahia and Instituto da Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia CEP 40296-710, Brazil.
Anthony P WestDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Gustavo Reyes-TeranNational Institute of Respiratory Diseases, Mexico City CP 14080, Mexico.
Albert I KoInstituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia CEP 40296-710, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520, USA.
Margaret R MacDonaldLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA. Electronic address: macdonm@rockefeller.edu.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA. Electronic address: nussen@rockefeller.edu.
Rockefeller University · USCalifornia Institute of Technology · USFundação Oswaldo Cruz · BRUniversidade Federal da Bahia · BRYale University · USHoward Hughes Medical Institute · US
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BAROUCH, DAN H. · 2012 to 2018
$131.5MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MUnderstanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0MResearch Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5MUnraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunityR01AI124690 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2016 to 2026
$8.3MNaturally-Acquired and Vaccine-Mediated Immunity to LeptospirosisR01AI121207 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG, REIS, MITERMAYER GALVAO DOS · 2016 to 2020
$6.4MClass Switch Recombination in B LymphocytesR37AI037526 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$5.4MGlobal Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2MSIGNALLING PATHWAYS IN AUTOIMMUNITYR01AI037526 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 1994 to 2012
$5.0MDisease Determinants of Urban LeptospirosisU01AI088752 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG · 2010 to 2014
$3.6MFIC NIH HHS D43 TW010540FIC NIH HHS R01 TW009504FIC NIH HHS R25 TW009338NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR001866NIAID NIH HHS R01 AI037526NIAID NIH HHS R01 AI121207NIAID NIH HHS R01 AI124690NIAID NIH HHS R21 AI112602NIAID NIH HHS R37 AI037526NIAID NIH HHS T32 AI070084NIAID NIH HHS U01 AI088752NIAID NIH HHS U19 AI057229NIAID NIH HHS U19 AI111825NIAID NIH HHS UM1 AI100663
Abstract
Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serum neutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralB-LymphocytesBrazilFemaleHumansImmunologic MemoryLeukocytes, MononuclearMaleMexicoMiceZika Virus InfectionAntibodies, NeutralizingAntibodies, Viralantibodiesdengue virusflavivirusstructurevaccineZika virus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.